Black Rock Inc. Cerevel Therapeutics Holdings, Inc. Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,560,931 shares of CERE stock, worth $0. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,560,931
Previous 5,448,620
34.65%
Holding current value
$0
Previous $230 Million
36.78%
% of portfolio
0.0%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding CERE
# of Institutions
242Shares Held
154MCall Options Held
2.19MPut Options Held
3.87M-
Bain Capital Investors LLC Boston, MA65.7MShares$065.37% of portfolio
-
Perceptive Advisors LLC New York, NY10.8MShares$012.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.54MShares$04.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.15MShares$00.01% of portfolio
-
Fil LTD Hamilton, D03.25MShares$00.14% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...